Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure

NCT ID: NCT02235077

Last Updated: 2017-06-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 360 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-30
• Study Completion Date: 2016-06-06

Brief Summary

The primary objective of this study is to test the hypothesis that high-dose spironolactone will lead to greater proportional reduction in NT-proBNP levels from randomization to 96 hours over standard of care.

Detailed Description

Mineralocorticoid receptor antagonist (MRA) therapy is recommended in stable chronic systolic heart failure (HF) and post-infarction HF patients for improving morbidity and mortality. MRA therapy in AHF and in high doses is less well studied. The effectiveness and safety of early high dose MRA therapy in AHF is supported by a single-blind study showing lower risk of worsening renal function and need for loop diuretics, and improved congestion. MRA therapy in AHF may improve outcomes by relieving congestion at higher doses through their natriuretic property, in addition to preventing the deleterious effects of exacerbation of neuro-hormonal activation by loop diuretics.

This randomized, double blind, placebo-controlled study of high-dose spironolactone vs. placebo (for patients not receiving MRA at home) or low-dose spironolactone (for patients already receiving low-dose spironolactone) in AHF, will enroll 360 participants at approximately 30 clinical centers. After obtaining informed consent, subjects who fulfill all the inclusion criteria and none of the exclusion criteria will be randomized. Randomization will be performed by using procedures determined by the Coordinating Center (CC).

• Patients receiving no MRA therapy at baseline will be randomized to receive either spironolactone 100 mg or placebo daily for 96 hours.
• Patients already receiving low-dose spironolactone at baseline (12.5 mg or 25 mg daily) will be randomized to 100 mg or 25 mg spironolactone daily for 96 hours.

Within 24 hours prior to randomization, all study participants will undergo:

• Medical History
• Review of medications including pre-hospital loop diuretics, MRA, and potassium doses
• Physical examination, vital signs and body weight
• Measurement of creatinine, blood urea nitrogen (BUN), and electrolytes
• Dyspnea Relief Assessments (7-point Likert and Visual Analog Scale)
• Serum pregnancy test for all women of childbearing potential
• Collection of samples for measurement of NT-proBNP levels (Core Lab)

Study drug will be initiated as follows:

• Patients receiving no MRA therapy at baseline: 4x25 mg study capsules once daily; starting dose 100 mg spironolactone or placebo; if dose adjustment is required, active capsules will be adjusted by pharmacy to achieve the required dose.
• Patients already receiving low-dose spironolactone at baseline: 4x25 mg study capsules once daily; one capsule containing 25 mg spironolactone and 3x25 mg study capsules containing spironolactone or placebo; if dose adjustment is required, active capsules will be adjusted by pharmacy to achieve the required dose.

Patients will be followed every 24 hours following randomization through 96 hours. Study drug will be administered daily for 96 hours. Study drug administration time is anchored to time of randomization. Dose adjustments (continue, hold, stop) are permitted according to serum K+ and renal function.

Assessment at 24 hours post randomization includes: Review of medications, body weight, fluid intake/urine output, creatinine, blood urea nitrogen (BUN), and electrolytes, and adverse events.

If the 24 hour assessment is also the day of discharge, include:

• Physical exam / Vital signs
• Dyspnea Relief (7-Point Likert and VAS) worksheets
• Biomarkers (NT-proBNP) (Core Lab)

Assessment at 48 hours post randomization includes: Review of medications, physical exam/vital signs, body weight, fluid intake/urine output, Dyspnea Relief (7-Point Likert and VAS) worksheets, creatinine, blood urea nitrogen (BUN), and electrolytes, biomarker levels (NT-proBNP) by Core Lab.

Assessment at 72 hours post randomization includes: Review of medications, body weight, fluid intake/urine output, creatinine, blood urea nitrogen (BUN), and electrolytes, and adverse events.

If the 72 hour assessment is also the day of discharge, include:

• Physical exam / Vital signs
• Dyspnea Relief (7-Point Likert and VAS) worksheets
• Biomarkers (NT-proBNP) (Core Lab)

Assessment at 96 hours post randomization includes: Review of medications, physical exam/vital signs, body weight, fluid intake/urine output, creatinine, blood urea nitrogen (BUN), and electrolytes, Dyspnea Relief (7-Point Likert and VAS), and biomarker levels (NT-proBNP) by Core Lab.

If patient is clinically euvolemic in less than 96 hours, the investigator may consider changing loop diuretics to oral dose.

Study drug will be discontinued after 96 hours and further use of MRA will be left to the treating physician's discretion.

Assessment at Discharge: If discharge occurs after the 96 hour assessment but prior to the 30 day follow-up telephone call,the following will be documented: Medication review (prescribed medications at the time of discharge), body weight (if available), creatinine, blood urea nitrogen (BUN), and electrolytes (if available), and adverse events.

Ejection fraction data will be obtained from echocardiogram within 6 months prior to randomization. Those patients who do not have an echocardiogram recorded within this time frame will get an echocardiogram, nuclear perfusion study, MRI, or MUGA performed prior to the 96 hour in-hospital assessment to ascertain ejection fraction.

Follow-up Telephone Call at Day 30: All participants will be contacted by telephone at day 30 (+3 days) following randomization to assess tertiary endpoints, including medication use and adverse events.

Follow-up Telephone Call at Day 60: All participants will be contacted by telephone at day 60 (+/-3 days) following randomization to assess vital status.

During the consent process, patients will be asked if interested in donating samples and data for research purposes via a biorepository and/or genetic study. Based on site and IRB preference, this optional part of the study may be incorporated into the main consent or may be a separate consent and IRB application.

Conditions

Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Spironolactone

Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours

Group Type: ACTIVE_COMPARATOR

Spironolactone

Intervention Type: DRUG

Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.

Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.

Placebo

Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.

Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.

Interventions

Spironolactone

Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.

Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.

Intervention Type: DRUG

Placebo

Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.

Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.

Intervention Type: DRUG

Other Intervention Names

aldactone

Eligibility Criteria

Inclusion Criteria

• Male or female patient ≥21 years old
• Admitted to hospital for AHF with at least 1 symptom (dyspnea, orthopnea, or fatigue) and 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography) of congestion
• Patient must be randomized within 24 hours of first IV diuretic dose administered for the current episode of decompensation (regardless of where the diuretic was given e.g. office, ED, ambulance, hospital etc.)
• Estimated GFR of ≥30 mL/min/1.73m2 determined by the MDRD equation
• Serum K+ ≤5.0 mmol/L at enrollment
• NT-proBNP ≥1000 pg/mL or BNP ≥250 pg/mL, measured within 24h from randomization
• Not on MRA or on low-dose spironolactone (12.5 mg or 25 mg daily) at baseline

Exclusion Criteria

• Taking eplerenone or >25 mg spironolactone at baseline
• eGFR < 30 ml/min/1.73m2
• Serum K+ >5.0 mmol/L. If a repeat measurement within the enrollment window is <5.0, the patient can be considered for inclusion.
• Systolic blood pressure <90 mmHg
• Hemodynamically significant arrhythmias or defibrillator shock within 1 week
• Acute coronary syndrome currently suspected or within the past 4 weeks
• Severe liver disease (ALT or AST >3 x normal, alkaline phosphatase or bilirubin >2x normal)
• Active infection (current use of oral or IV antimicrobial agents)
• Active gastrointestinal bleeding
• Active malignancy other than non-melanoma skin cancers
• Current or planned mechanical circulatory support within 30 days
• Post cardiac transplant or listed for transplant and expected to receive one within 30 days
• Current inotrope use
• Complex congenital heart disease
• Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade
• Previous adverse reaction to MRAs
• Enrollment in another randomized clinical trial during index hospitalization

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Duke University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adrian Hernandez, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University Health Systems

Eugene Braunwald, MD

Role: STUDY_CHAIR

Harvard University

Locations

Emory University School of Medicine

Atlanta, Georgia, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

Tufts Medical Center

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Boston VA Healtcare System

West Roxbury, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Washington University

St Louis, Missouri, United States

Saint Louis University Hospital

St Louis, Missouri, United States

Stony Brook University Medical Center

Stony Brook, New York, United States

Duke University

Durham, North Carolina, United States

Southeastern Regional Medical Center

Lumberton, North Carolina, United States

University Hospitals - Case Medical Center

Cleveland, Ohio, United States

Metro Health System

Cleveland, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

Lancaster General Hospital

Lancaster, Pennsylvania, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Jefferson Medical College

Philadelphia, Pennsylvania, United States

Michael Debakey VA Medical Center

Houston, Texas, United States

University of Utah School of Medicine

Salt Lake City, Utah, United States

Utah VA Medical Center

Salt Lake City, Utah, United States

The University of Vermont- Fletcher Allen Health Care

Burlington, Vermont, United States

Countries

United States

References

Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.

Reference Type: DERIVED

PMID: 33107592 (View on PubMed)

Greene SJ, Felker GM, Giczewska A, Kalogeropoulos AP, Ambrosy AP, Chakraborty H, DeVore AD, Fudim M, McNulty SE, Mentz RJ, Vaduganathan M, Hernandez AF, Butler J. Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. Can J Cardiol. 2019 Sep;35(9):1097-1105. doi: 10.1016/j.cjca.2019.01.022. Epub 2019 Feb 7.

Reference Type: DERIVED

PMID: 31230825 (View on PubMed)

Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, McNulty SE, Mentz RJ, Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, Braunwald E; National Heart Lung and Blood Institute Heart Failure Clinical Research Network. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol. 2017 Sep 1;2(9):950-958. doi: 10.1001/jamacardio.2017.2198.

Reference Type: DERIVED

PMID: 28700781 (View on PubMed)

Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, Tang WH, Felker GM, Shah MR, Braunwald E. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail. 2016 Sep;4(9):726-35. doi: 10.1016/j.jchf.2016.06.003. Epub 2016 Aug 10.

Reference Type: DERIVED

PMID: 27522631 (View on PubMed)

Other Identifiers

5U01HL084904

Identifier Type: NIH

Identifier Source: secondary_id

View Link

Pro00057090

Identifier Type: -

Identifier Source: org_study_id